150 results
8-K
EX-2.2
ORTX
Orchard Therapeutics plc
24 Jan 24
Termination of a Material Definitive Agreement
4:17pm
into account its safety, tolerability and efficacy, its proprietary position and profitability (including pricing and reimbursement status), projected
DEFA14A
ORTX
Orchard Therapeutics plc
30 Nov 23
Additional proxy soliciting materials
4:13pm
registrational trial in December to evaluate the efficacy and safety of OTL-203 compared to allogeneic HSCT.”
OTL-203 has previously received Rare Pediatric … generally well-tolerated with a safety profile consistent with the selected conditioning regimen. The viral vector integration profile was consistent
8-K
EX-99.1
ORTX
Orchard Therapeutics plc
30 Nov 23
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
4:06pm
to initiating our global registrational trial in December to evaluate the efficacy and safety of OTL-203 compared to allogeneic HSCT.”
OTL-203 has … , treatment with OTL-203 has been generally well-tolerated with a safety profile consistent with the selected conditioning regimen. The viral vector
DEFM14A
ORTX
Orchard Therapeutics plc
16 Nov 23
Proxy related to merger
4:45pm
or severity of any previously identified side effects, adverse effects, adverse events or safety observations or reports of new side effects, adverse … effects, adverse events or safety observations, in each of (A) – (F), solely to the extent not resulting from or arising out of any wrongdoing, fraud
8-K
EX-99.1
zbm5yewq4
13 Nov 23
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
7:05am
PREM14A
g1zlac7q9desv1vi87
3 Nov 23
Preliminary proxy related to merger
5:11pm
8-K
EX-99.1
2pern
26 Oct 23
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
4:35pm
DEFA14A
pq7 ov1qik
17 Oct 23
Additional proxy soliciting materials
4:32pm
DEFA14C
s93wz 856ffoxmv
5 Oct 23
Additional information
4:48pm
DEFA14C
3hhmceetgvit0hxq
5 Oct 23
Additional information
4:45pm
DEFA14C
ujcp04 wnljv058
5 Oct 23
Additional information
4:40pm
DEFA14A
yumoyns
5 Oct 23
Additional proxy soliciting materials
9:07am
8-K
EX-2.1
bvvkyxd ja6sxk
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
8-K
EX-99.1
e0i3sq pbq96uf
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
8-K
EX-99.1
nqye 08rcdph7
18 Sep 23
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
7:07am
8-K
EX-99.2
davme3ck6s
3 Aug 23
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
7:05am
8-K
EX-99.1
ho6yni0ph
3 Aug 23
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
7:05am
8-K
EX-99.3
edp1 y96ksrexf2
23 May 23
Regulation FD Disclosure
7:06am